Check whether a name resolves to a research listing, investigational program, or approved medicine, then open the exact product and seller records for the destination country.
Start with a peptide name and destination. The result shows what the name means in our evidence database and which local records must be checked next.
Status check updated to Retatrutide in 대한민국. Not approved or available for public use; verify Korea product and provider records.
Lilly states that retatrutide has not been approved by any regulatory agency, is not available for public use, and is legally available only through Lilly-sponsored clinical trials. A South Korean listing cannot inherit that clinical identity. Check the exact pharmaceutical-product authorization in the MFDS public dataset and verify the provider or pharmacy separately through the HIRA service before interpreting any local offer.
This is an investigational program, not an approved product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, or regulatory status.
대한민국에서 펩타이드, 펩타이드 의약품, 체중 관리 약물, 연구용 물질을 검색할 때 식품의약품안전처 의약품 허가 데이터와 건강보험심사평가원 병원·약국 찾기를 이용하는 검증 가이드입니다. 국내 상품, 수입품, 병원 서비스, 연구용 표시를 같은 범주로 합치지 않고 제품과 기관의 공식 기록을 분리해 확인합니다.
This check routes each question to the right record. It is not a medical recommendation, legal opinion, local availability claim, or commercial ranking.
Each selection has a shareable URL, so you can send someone the exact peptide and destination without losing the identity or country context.
The short answer is a routing decision, not a blanket legal, medical, or availability conclusion.
No region-wide answer is supportable from a seller page or a single database. Resolve the BPC-157 identity, choose the exact destination, then check that country’s product and seller or supply records.
The Peptide Local identity record places retatrutide in the investigational clinical-program lane. A seller-labelled vial cannot inherit the sponsor’s trial material, evidence, or regulatory status.
No. The FDA reference resolves the US medicine identity. Authorization, presentation, prescription status, current market presence, and seller authority must still be confirmed in the selected country.
Keep the active ingredient, research label, clinical program, sponsor code, and approved brand attached to their proper source.
Open the national product database and the separate pharmacy, establishment, professional, seller, or supply record linked for that country.
Match the legal seller identity, product presentation, claimed category, current status, and delivery route. Do not transfer evidence between unlike products.